|
| 37951974 | Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. | Br J Cancer | 2024 |
| 36344859 | Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. | J Immigr Minor Health | 2023 |
| 38072759 | Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. | Eur Urol Oncol | 2023 |
| 37620428 | Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. | Prostate Cancer Prostatic Dis | 2023 |
| 37922930 | Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. | Lancet Oncol | 2023 |
| 36952634 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 37316414 | Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. | Clin Genitourin Cancer | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37399894 | Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. | Ann Oncol | 2023 |
| 36996380 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). | J Clin Oncol | 2023 |
| 37091148 | Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer. | Front Oncol | 2023 |
| 36649492 | Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. | JCO Oncol Pract | 2023 |
| 36435709 | Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. | Urol Oncol | 2023 |
| 36528473 | Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. | Urol Oncol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36209239 | Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. | Prostate Cancer Prostatic Dis | 2023 |
| 36351060 | Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. | Cancer Res | 2023 |
| 34479838 | Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. | Eur Urol Focus | 2022 |
| 35584338 | Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. | JCO Clin Cancer Inform | 2022 |
| 35348771 | COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. | Oncologist | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35504836 | Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). | Eur Urol Focus | 2022 |
| 35750560 | Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. | Urol Oncol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35859180 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. | Nature | 2022 |
| 36212187 | Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. | Prostate Cancer | 2022 |
| 36109521 | Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. | Nat Commun | 2022 |
| 36383412 | The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. | Elife | 2022 |
| 36301577 | Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. | JAMA Oncol | 2022 |
| 36260524 | Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35973929 | Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. | Urol Oncol | 2022 |
| 35321431 | APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. | Front Oncol | 2022 |
| 34916086 | Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. | Eur Urol | 2022 |
| 35176163 | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 34932386 | Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. | JCO Oncol Pract | 2022 |
| 34965953 | Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). | Clin Cancer Res | 2022 |
| 35196064 | Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. | JCO Oncol Pract | 2022 |
| 34844839 | Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. | Eur J Cancer | 2022 |
| 32286548 | Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 35559801 | Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. | J Cancer Policy | 2021 |
| 33571636 | Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. | Ann Oncol | 2021 |
| 33823065 | Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. | Cancer | 2021 |
| 33621447 | Examining reporting and representation of patients with cancer in COVID-19 clinical trials. | Cancer Rep (Hoboken) | 2021 |
| 33840559 | Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. | Eur Urol | 2021 |
| 33780276 | Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). | J Urol | 2021 |
| 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 34934057 | The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. | Nat Commun | 2021 |